Kodiak Sciences/$KOD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kodiak Sciences
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Ticker
$KOD
Sector
Primary listing
Employees
121
Headquarters
Website
Kodiak Sciences Metrics
BasicAdvanced
$488M
-
-$3.79
2.42
-
Price and volume
Market cap
$488M
Beta
2.42
52-week high
$11.42
52-week low
$1.92
Average daily volume
595K
Financial strength
Current ratio
3.48
Quick ratio
3.359
Long term debt to equity
76.716
Total debt to equity
92.776
Profitability
EBITDA (TTM)
-188.886
Management effectiveness
Return on assets (TTM)
-39.38%
Return on equity (TTM)
-140.33%
Valuation
Price to book
6.94
Price to tangible book (TTM)
6.94
Price to free cash flow (TTM)
-4.213
Free cash flow yield (TTM)
-23.74%
Free cash flow per share (TTM)
-2.196
Growth
Earnings per share change (TTM)
0.71%
3-year earnings per share growth (CAGR)
-17.15%
What the Analysts think about Kodiak Sciences
Analyst ratings (Buy, Hold, Sell) for Kodiak Sciences stock.
Bulls say / Bears say
Kodiak finished Q2 2025 with $104.2 million in cash and equivalents, enough to fund operations into 2026 as it advances clinical development (Reuters).
The company has completed commercial-scale batches at its URSUS manufacturing site ahead of planned BLA submissions, showcasing advanced manufacturing readiness (Reuters).
R&D spending grew in Q2 driven by active Phase 3 trials for tarcocimab, KSI-501, and KSI-101—underscoring the strong momentum in its late-stage pipeline (Reuters).
Net loss in Q2 2025 widened to $54.3 million, falling short of analyst estimates and highlighting persistently high cash burn (Reuters).
With Q2 operating expenses of $55.51 million versus a $104.2 million cash balance, Kodiak may need to secure more financing before it receives results from key trials, in order to keep its development programs running (Reuters).
Kodiak is still pre-commercial with no product revenues, and Wall Street’s median 12-month price target of $3.50 points to limited potential upside at current prices (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Kodiak Sciences Financial Performance
Revenues and expenses
Kodiak Sciences Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kodiak Sciences stock?
Kodiak Sciences (KOD) has a market cap of $488M as of September 17, 2025.
What is the P/E ratio for Kodiak Sciences stock?
The price to earnings (P/E) ratio for Kodiak Sciences (KOD) stock is 0 as of September 17, 2025.
Does Kodiak Sciences stock pay dividends?
No, Kodiak Sciences (KOD) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Kodiak Sciences dividend payment date?
Kodiak Sciences (KOD) stock does not pay dividends to its shareholders.
What is the beta indicator for Kodiak Sciences?
Kodiak Sciences (KOD) has a beta rating of 2.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.